No Advisory Committee Meeting Currently Planned to Review the ApplicationIf approved, 1st Gene Therapy in U.S. for the Treatment of Any Type of HemophiliaFDA Also Accepts Premarket Approval (PMA) Application for Companion Diagnostic Test, a 1st for a G… […]
PH10, a Neurosteroid Nasal Spray, Demonstrated Significant Rapid-Onset Antidepressive Benefit versus Placebo, without Psychological Side Effects or Safety Concerns Often Associated with Ketamine-based Therapy
SOUTH SAN FRANCISCO, Calif., Feb. 20, 202… […]
SAN FRANCISCO, Feb. 20, 2020 /PRNewswire/ — Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 9th Annual SVB Leerink Global… […]
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020. Rigel … […]
— Increased annual revenue by approximately 47% and annual volume by nearly 60% year-over-year —- Issued 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both v… […]
Bonifatius Hospital in Lingen to Be Among the First in Europe to Offer the Latest Advances in Stereotactic Radiosurgery
SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ — ZAP Surgical Systems, Inc. today announced an agreement with Bonifatius Hospital… […]
NEWARK, Calif., Feb. 19, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a corporate overview at the upcoming the SVB Leerink 9th Annu… […]
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 /PRNewswire/ — VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet … […]
– Onvansertib demonstrates efficacy in Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC) across known androgen receptor resistance mechanisms- Onvansertib-induced decreases in circulating tumor cells (CTCs) is a surrogate for ef… […]
SAN JOSE, Calif., Feb. 13, 2020 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and NanoPin Technologies, Inc., the developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood… […]
© 2019 San Francisco Biotechnology Network
